Pfizer files supplemental applications to FDA, EMA for Prevnar 13
Prevnar 13, which is based on the scientific foundation of Prevnar, was approved for use in infants and young children in Europe in December 2009 and in the
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.